Pulmonary toxicity associated with erlotinib

Area of Science:

• Pulmonology
• Oncology
• Pharmacology

Background:

• Interstitial lung disease (ILD) is a known adverse effect of gefitinib therapy.
• The pulmonary toxicity of erlotinib, another EGFR inhibitor, is less understood.
• Non-small cell lung cancer (NSCLC) patients are often treated with tyrosine kinase inhibitors like erlotinib.

Observation:

• A patient with advanced NSCLC developed fatal pulmonary toxicity after receiving erlotinib.
• This patient had pre-existing usual interstitial pneumonia (UIP) findings on a resected lung specimen before erlotinib treatment.

Findings:

• This case highlights the potential for erlotinib to cause severe, fatal ILD.
• Patients with pathological UIP findings or pre-existing pulmonary fibrosis may be at increased risk.
• Erlotinib-induced ILD can mimic other pulmonary conditions, complicating diagnosis.

Implications:

• Clinicians should consider erlotinib-induced ILD in patients presenting with new or worsening respiratory symptoms.
• Pre-treatment screening for pulmonary fibrosis or UIP may be warranted in at-risk patients.
• Further research is needed to elucidate the mechanisms and incidence of erlotinib-induced pulmonary toxicity.